Moleculin Biotech (MBRX) EPS (Basic) Growth (1y) (2017 - 2026)
Moleculin Biotech (MBRX) EPS (Basic) Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 322.67% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 96.41% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -16.29% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -147.33% |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.11% |
| Dec 31, 2025 | 86.82% |
| Sep 30, 2025 | 91.75% |
| Jun 30, 2025 | 84.84% |
| Mar 31, 2025 | 76.46% |
| Dec 31, 2024 | 57.13% |
| Sep 30, 2024 | 35.82% |
| Jun 30, 2024 | 24.90% |
| Mar 31, 2024 | 37.89% |
| Dec 31, 2023 | -21.84% |
| Sep 30, 2023 | 36.91% |
| Jun 30, 2023 | 16.87% |
| Mar 31, 2023 | -17.34% |
| Dec 31, 2022 | -27.06% |
| Sep 30, 2022 | -46.77% |
| Jun 30, 2022 | -33.93% |
| Mar 31, 2022 | 11.39% |
| Dec 31, 2021 | 27.26% |
| Sep 30, 2021 | 34.60% |
| Jun 30, 2021 | 61.83% |